About Zogenix
Zogenix is a company based in Emeryville (United States) founded in 2006 by Bret Megargel was acquired by UCB in January 2022. Zogenix has raised $149.06 million across 7 funding rounds from investors including Blackstone, UCB and CIT. Zogenix has completed 2 acquisitions, including Brabant Pharma and Modis Therapeutics. Zogenix operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Heron Therapeutics, among others.
- Headquarter Emeryville, United States
- Founders Bret Megargel
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zogenix, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$149.06 M (USD)
in 7 rounds
-
Latest Funding Round
$251.3 M (USD), Post-IPO
Oct 04, 2017
-
Investors
Blackstone
& 9 more
-
Employee Count
Not available
-
Investments & Acquisitions
Brabant Pharma
& 1 more
-
Acquired by
UCB
(Jan 19, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Zogenix
Unlock access to complete
Software Development Team
219 people
Leadership Team
92 people
Head Team
57 people
Global Team
39 people
Senior Team
36 people
Operations Team
36 people
Product Management Team
34 people
Human Resources and Administration
22 people
Unlock access to complete
Funding Insights of Zogenix
Zogenix has successfully raised a total of $149.06M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $251.3 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zogenix
Zogenix has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, UCB and CIT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments are focused on US companies.
|
Locked | Locked | Locked |
Investor details for Zogenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zogenix
Zogenix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Brabant Pharma and Modis Therapeutics.
Investment portfolio details for Zogenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for rare genetic mitochondrial diseases are developed.
|
Locked | Locked | 2016 | Locked | |
|
Therapeutics for rare CNS diseases like Dravet Syndrome were developed.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Zogenix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Zogenix
Detailed financials for Zogenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zogenix Comparisons
Peer comparison for Zogenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zogenix
Zogenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Heron Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
Detailed competitors of Zogenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zogenix
Complete news archive for Zogenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zogenix
Zogenix was founded in 2006.
Zogenix is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Zogenix is a funded company, having raised a total of $149.06M across 7 funding rounds to date.
Zogenix was founded in 2006 as a specialty pharmaceutical company based in Emeryville, United States. Late-stage product candidates are advanced for treating central nervous system disorders and pain. The lead candidate, sumatriptan DosePro, facilitates needle-free subcutaneous administration of sumatriptan for acute migraine relief. ZX002, the second candidate, provides a controlled-release form of hydrocodone targeted at chronic pain management.
Zogenix's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Zogenix has made 2 acquisitions, including Brabant Pharma, and Modis Therapeutics.
Zogenix has 10 investors. Key investors include Blackstone, UCB, CIT, Oxford Finance, and HealthCare Royalty Partners.